Ignite Creation Date:
2024-05-05 @ 11:28 AM
Last Modification Date:
2024-10-26 @ 9:08 AM
Study NCT ID:
NCT00050609
Status:
COMPLETED
Last Update Posted:
2007-11-20
First Post:
2002-12-16
Brief Title:
Study of Tadalafil for the Treatment of Diabetic Patients With Symptoms of Upset Stomach and Delayed Stomach Emptying
Sponsor:
Eli Lilly and Company
Organization:
Eli Lilly and Company
Study Overview
Official Title:
A Randomized Double-Blind Placebo-Controlled Parallel Study of IC351 LY450190 in Patients With Diabetic Gastroparesis
Status:
COMPLETED
Status Verified Date:
2007-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purposes of this study are to determine whether an experimental drug known as tadalafil can reduce symptoms of dyspepsia fullness after eating inability to finish a regular meal bloating discomfort or pain in the upper abdomen belching after meals nausea vomiting in diabetic patients andor reduce the amount of time the stomach takes to empty the contents of a standard meal The safety of tadalafil given once daily for 8 weeks in this population will also be studied
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| H6D-MC-LVDC | None | None | None |